WWW.PERFECTDISPLAY.COM - Where Technology Converges

MEDICAL AND BIOTECHNOLOGY FINANCIALS

Home | Beauty and Health | EDA News | Medical Technology Journal | Micromachnes and Nanomachines Database | Semiconductor Evening News | World Energy Technololgy | NAVIGATION | E-MAGAZINES | E-DIRECTORIES | NEWSWIRES | PRESENTATIONS | BUSINESS INTELLIGENCE | Rebuilding New Orleans | Story Book Corner - Coloring Books and More | SEARCH THE SITE | IC Companies By Alphabet - S | NFL Football | List Your Company Profile | Halloween Fun | Greeting Cards

August 26th, 2005
 
MicroDental Reports Record Breaking Fiscal 2005 Revenue
 
MicroDental Laboratories, which considers itself one of the leading advanced cosmetic dental laboratories, has announced that revenue for its fiscal year 2005 ended June 30 was a record. The company indicated that its growth was led by its Micro Advanced Cosmetics (MAC) Division. The company attributes that division's growth to its advanced materials development, CAD/CAM and color matching technology. The company indicates that its MAC Veneers are recommended three times more often by dentists than other porcelain high-end veneer brands.

August 16th, 2005
 
 
Forbes Medi-Tech Inc. (NASDAQ:FMTI)(TSX:FMI), a company that has a cholesterol-lowering ingredient now used in yogurt, has reported a 112 percent increase in its second quarter revenue. The company’s revenue, in Canadian dollars for the three months ended June 30, 2005, was $6.73 million compared to $3.18 million for the same period in 2004. For the latest six month period, also ended June 30 2005 and in Canadian dollars was $11.45 million compared to $6.44 million for the six months ended June 30, 2004. The company for the entire 2005 year has maintained its revenue guidance at between $21 million and $22 million.
 
Commenting on the quarter was Charles Butt, CEO at Forbes Medi-Tech Inc. "In the second quarter, we demonstrated record growth in our ingredient business and increased activity in our core research and development programs. The granting of the European patent for FM-VP4 is a significant milestone in the drug's development path. The successful grant of the patent parallels the Company's progress in its efforts to complete its IND application for FM-VP4's planned US Phase II trial."
 
The company in its report noted that Kesko of Finland launched a yogurt that includes its cholesterol-lowering ingredient in May 2005.

 

 

 
Copyright 2004, 2005, Mark C. Stansberry, All Rights Reserved
 
TERMS OF USE
 
The publisher of this web site does not certify that the information contained on this web site is 100 percent accurate. Use of this web site requires that the reader release the publisher from all liability that may result from the reliance of information on this web site. The publisher suggests that readers verify any information contained on this web site with three or more other reference sources, as well as directly with any company(s) mentioned. Please report any errors or omissions to marketing@perfectdisplay.com.
 
The site may include words, or phrases that are specific trademarks of companies mentioned.